Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

NCT00859937 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

NIH

Sponsor class

Conditions

Malignant Salivary Gland Neoplasm
Recurrent Salivary Gland Carcinoma
Salivary Gland Adenoid Cystic Carcinoma
Stage IV Major Salivary Gland Cancer AJCC v7

Interventions

DRUG: Dasatinib
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)